Pavel Klein, MD
Neurology · Bethesda, MDNPI 1770528648
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by SK Life Science, Inc. at 39.7% of the total. Reporting peaked in 2020 at $156,884 and has fallen 76.3% since, to $37,154 in 2025. Among neurology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,045 payments — averaging $678.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$281K
- UCB, Inc.$153K
- Eisai Inc.$73K
- UCB SA$62K
- Neurelis, Inc.$40K
- Dr.reddy's Laboratories,inc.$24K
- plus $75K from 41 others
Across 442 payments — averaging $5925.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$949K
- Neurelis, Inc.$376K
- UCB SA$276K
- Daiichi Sankyo Inc.$223K
- Takeda Pharmaceuticals U.S.A., Inc.$206K
- Eisai Inc.$185K
- plus $404K from 13 others
What the payments were for
- Consulting fees$217,51831%
- Speaking & faculty fees$384,01354%
- Travel & lodging$85,52412%
- Food & beverage$20,5563%
- Education$1,2440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$708,856 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 495 | $771,726 |
| BriviactBrivaracetam | 232 | $370,897 |
| WakixPitolisant Hcl | 12 | $164,099 |
| LamictalLamotrigine | 23 | $127,690 |
| AptiomEslicarbazepine Acetate | 46 | $99,219 |
| Lacosamide | 526 | $93,072 |
| VimpatLacosamide | 38 | $73,525 |
| EpidiolexCannabidiol (Cbd) | 15 | $64,151 |
| FycompaPerampanel | 14 | $30,626 |
| Depakote ErDivalproex Sodium | 33 | $30,313 |
| NayzilamMidazolam | 17 | $25,621 |
| KeppraLevetiracetam | 11 | $20,948 |
| Levetiracetam | 269 | $14,784 |
| Lamotrigine ErLamotrigine | 67 | $11,972 |
| Clobazam | 98 | $11,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $281,441 | $771,726495 claims |
| UCB, Inc.Briviact, Vimpat, Nayzilam | $153,262 | $470,043287 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $4,846 | $99,21946 claims |
| Eisai Inc.Fycompa | $73,081 | $30,62614 claims |
| UCB SAKeppra | $62,450 | $20,94811 claims |
| Dr.reddy's Laboratories,inc.Levetiracetam, Divalproex Sodium, Lamotrigine, Pregabalin | $24,367 | $19,274464 claims |
| Upsher-smith Laboratories LLCTopiramate | $109 | $79458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 neurology providers in Maryland.
Other neurology in Bethesda
- Jose MasdeuBethesda$56K
- Wilson BryanBethesda$42K
- Daniel BeckerLutherville$1.6M
- Sangjin OhGlen Burnie$1.5M
- Ruwani GunawardaneFulton$479K
- Michael PolydefkisBaltimore$371K
- David CornblathLutherville$345K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Bruce RabinLutherville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.